Rigel Pharmaceuticals Grants Stock Awards to Non-Executive Employees
SOUTH SAN FRANCISCO, Calif. – January 9, 2026 – Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) has announced the issuance of stock options and restricted stock units to 11 non-executive employees as part of its Inducement Plan. This move, approved by Rigel’s Compensation Committee, is designed to incentivize new hires, aligning with NASDAQ Listing Rule 5635(c)(4), which permits such grants as a material inducement for employment.
The company awarded 24,775 stock options and 16,555 restricted stock units. These awards will vest over a four-year period, featuring a one-year cliff, meaning no vesting occurs until the first anniversary of the grant date, after which a portion vests, followed by incremental vesting thereafter.
This strategic use of equity-based compensation is a common practice in the biotechnology and pharmaceutical sectors, particularly for emerging or growth-stage companies. It serves a dual purpose: attracting and retaining top talent in a highly competitive industry and aligning the financial interests of employees with those of shareholders. By offering a stake in the company’s future success, Rigel aims to foster a culture of ownership and drive performance.
The timing of these grants also warrants attention. As Rigel continues to advance its pipeline and potentially expand the commercial reach of its existing therapies, the company is likely focused on building out its operational and scientific teams. Robust employee incentives are a critical component of this growth strategy, ensuring that Rigel can attract individuals with the specialized skills needed to navigate the complex drug development and commercialization landscape.
Rigel Pharmaceuticals is a biopharmaceutical company committed to developing innovative therapies for patients suffering from hematologic disorders and cancer. Founded in 1996 and headquartered in South San Francisco, California, the company’s efforts are focused on addressing unmet medical needs through scientific advancement and strategic talent acquisition. Rigel’s current portfolio and development pipeline reflect its dedication to improving patient outcomes in challenging disease areas.
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/15519.html
